Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1BEZAFIBRATE
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[8] 20, 93, 94, 160, 296, 316, 324, 344 💬
2Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 94 💬
3Bezafibrate (drug)
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 316 💬
4Bezafibrate (INN 3968)
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 324 💬
5Bezafibrate 100 mg
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
6Bezafibrate 200 MG
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
7Bezafibrate 200 mg in addition to UDCA therapy
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
8Bezafibrate 200 MG Oral Tablet
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
9Bezafibrate 400 MG
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
10Bezafibrate 400 mg in addition to UDCA therapy
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
11Bezafibrate IR
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
12Bezafibrate SR
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
13Bezafibrate, Beza, BZF, Bezalip
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
14Bezafibrate, Beza, BZF, Bezalip mono
(D01366)		[1] Bezafibrate[1] Bezafibrate (D01366) 💬 [1] PPARA 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬